Skip to content
Screener

Stock Issuance Proceeds at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$32.9M+186%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$26K-60.0%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$3.21M+219%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$1.59M
Polaryx Therapeutics, Inc. logo
Polaryx Therapeutics, Inc.PLYX
$250K-86.3%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$23.6M-26.5%

Other financials

Income statement

See full
Revenue--100%
Operating income-$96.9M-27.4%
Net income-$83.7M-17.7%
EPS (diluted)-$2.87+13.3%

Balance sheet

See full
Cash & equivalents$474.8M+201%
Total debt$1.1M+44.0%
Total equity$1.3B+232%
Total assets$1.4B+207%

Cash flow

See full
Operating cash flow-$77.5M-41.8%
CapEx$245.0K+338%
Free cash flow-$77.8M-42.1%

Valuation

See full
Market cap$8.9B+909%
Enterprise value$8.43B+1,037%

Profitability

See full
Operating margin-3,927.5%-1,497pp
Net margin-3,658.5%-1,388pp
FCF margin-3,067.4%-1,030pp

Returns & leverage

See full
Return on equity-38.9%-10.3pp
Debt / equity0.0×
Current ratio15.7×+9.4×

Where this comes from

Reported directly by Praxis Precision Medicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The source filing: Praxis Precision Medicines, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 8:32 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001689548-26-000083
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Issuance of common stock from follow-on public offering, net of underwriting discounts, commissions and offering costs621,235
Proceeds from at-the-market offerings, net of issuance and commission costs83,263
Payments of tax withholdings related to vesting of restricted stock units(13,233)(1,218)
Proceeds from exercise of stock options and employee stock purchase plan purchases6,001854
Net cash provided by financing activities614,00382,899
Increase (decrease) in cash, cash equivalents and restricted cash117,016(57,957)
Cash, cash equivalents and restricted cash, beginning of period357,745215,788
Cash, cash equivalents and restricted cash, end of period$474,761$157,831

Item 1. Financial Statements (Unaudited)

FAQ

What is Praxis Precision Medicines, Inc.'s stock issuance proceeds?
Praxis Precision Medicines, Inc. (PRAX) reported stock issuance proceeds of $4.88M in Q2 2026.
How has Praxis Precision Medicines, Inc.'s stock issuance proceeds changed year-over-year?
Praxis Precision Medicines, Inc.'s stock issuance proceeds increased by 1560.5% year-over-year, from $294K to $4.88M.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Ask your AI about Praxis Precision Medicines, Inc.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude